University of Massachusetts Medical School

Post Doctoral Associate

Minimum Salary US-MA-Worcester
Job Location 5 months ago(9/17/2020 2:06 PM)
Requisition Number
2020-35616
# of Openings
1
Posted Date
Day
Shift
Exempt
Exempt/Non-Exempt Status
Non Union Position-W63-Residents/Post Docs

Overview

The Horae Gene Therapy Center of the University of Massachusetts Medical School is seeking applicants for a postdoctoral position to explore the AAV biology and AAV vector development. The candidate will work in a project focusing on a deep understanding of the cellular processes involved in successful gene therapies. We are looking for applicants with a Ph.D. or MD/Ph.D. in Biochemistry, Cell biology, Virology, or related disciplines with primary authorship on relevant publications in peer-reviewed scientific journals. The applicants should have strong hands-on experience working with and analyzing cellular and in vivo models as well as establishing novel methods. S/he is expected to have excellent problem solving, critical thinking, and presentation skills (written and oral), and the ability to generate high-quality data in a time-sensitive environment . The Postdoctoral Scholar will join a multidisciplinary collaborative team and participate in extramural collaborations with the ultimate goal to develop AAV gene therapies for life threatening diseases. We offer competitive salaries based on experience and track records and the possibilitiy to have excellent training opportunities.

For further information, please send a cover letter, CV and contact information of three references to Elisabet Mandon, Ph.D., Associate Professor Horae Gene Therapy Center & RNA Therapeutics Institute, University of Massachusetts Medical School AS6-2061, 368 Plantation Street Worcester, MA 01605 Phone: (508)-942-7029 E-mail: elisabet.mandon@umassmed.edu. The UMMS is proud of the power of its diverse community and encourages the application of  candidates with different background.

Options

Sorry the Share function is not working properly at this moment. Please refresh the page and try again later.
Share on your newsfeed